• Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer
  • News
  • Contact
    • Directions

News

News Subscription

Nov 25. 2020
Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China
Read more
Download
Nov 06. 2020
Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia
Read more
Download
Oct 28. 2020
Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer
Read more
Download
Oct 26. 2020
Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020
Read more
Download
Oct 13. 2020
Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer
Read more
Download
Oct 12. 2020
Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020
Read more
Download
Sep 29. 2020
Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer
Read more
Download
Sep 28. 2020
Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
Read more
Download
Sep 22. 2020
Basilea reports data from poster presentations at ESMO Virtual Congress 2020
Read more
Download
Aug 11. 2020
Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19
Read more
Download
  • previous
  • 1
  • …
  • 12
  • 13
  • 14
  • …
  • 32
  • next
  • Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer

Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

P: +41 61 606 11 11
E-mail: info@basilea.com

News subscription
  • Imprint
  • Terms of use and Privacy Notice
  • EFPIA Disclosure Code
  • Expanded Access Policy
  • Transparence des liens d’intérêt

© 2026 Basilea Pharmaceutica Ltd, Allschwil